Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

22 Boston Wharf Road, Floor 7, Boston, United States

Nick1971 May. 9 at 12:08 AM

$AKTX I sold every share before split and opened a new account with $2,000 Made this in last 2wks trading with @smartertrader I’ll never waste my time on a bio stock again unless scalp trade on a run. This stock is forever dead to me and I made 10x my loss here. I did enjoy the fun with the longs here

0 · Reply

topstockalerts May. 5 at 11:31 PM

After Hours Top Gainers PT2 $COMP $SMCI $FLEX $CYPH $AKTX

0 · Reply

Amricanopyscho May. 5 at 10:42 PM

$AKTX went on low volume

0 · Reply

MTN May. 5 at 3:04 PM

$AKTX still needs over a 3000% run up to make holders of the last few years whole. Just break even.

0 · Reply

MTN May. 5 at 3:03 PM

$AKTX just trying to sucker in buyers. Until they announce a major partnership, this is just MMs and traders trying to take your hard earned money. Don't believe me? Look at the chart.

0 · Reply

KayJ_ May. 4 at 8:57 PM

$AUUD $PAVS $MODD $AKTX into

0 · Reply

coachmc Apr. 29 at 6:27 PM

$AKTX the volume here is laughable , also the MC and spread

0 · Reply

BillionerOfKing Apr. 28 at 1:34 PM

$AKTX Current Stock Price: $5.60

0 · Reply

MTN Apr. 27 at 3:37 PM

$AKTX -$2,114.55 (99.74%) down from the ATH. Don't waste your time here.

0 · Reply

Stock_Catcher Apr. 27 at 12:35 PM

$AKTX Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

0 · Reply

Akari Therapeutics receives Australian patent for core payload technology

Apr 27, 2026, 8:35 AM EDT - 12 days ago

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Apr 21, 2026, 9:00 AM EDT - 18 days ago

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

2026-04-20T14:32:23.000Z - 19 days ago

Akari Therapeutics announces presentation of preclinical data for AKTX-101

Apr 20, 2026, 8:35 AM EDT - 19 days ago

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

2026-04-09T13:05:47.000Z - 4 weeks ago

Akari Therapeutics downgraded to Hold from Buy at Maxim

Apr 9, 2026, 8:50 AM EDT - 4 weeks ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

2026-04-08T12:08:04.000Z - 4 weeks ago

Akari Therapeutics downgraded to Hold from Buy at Maxim

2026-04-06T13:20:35.000Z - 4 weeks ago

Akari Therapeutics announces strategic partnership with WuXi XDC

Apr 6, 2026, 8:45 AM EDT - 4 weeks ago

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

2026-04-01T10:13:11.000Z - 5 weeks ago

Akari Therapeutics target adjusted to $27 from $1.60 at H.C. Wainwright

2026-03-30T23:51:11.000Z - 5 weeks ago

Akari Therapeutics trading halted, news pending

Mar 18, 2026, 8:05 AM EDT - 7 weeks ago

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Mar 17, 2026, 4:30 PM EDT - 7 weeks ago

Akari Therapeutics Announces ADS Ratio Change

Mar 13, 2026, 9:15 AM EDT - 2 months ago

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

2026-02-26T14:24:15.000Z - 2 months ago

Akari Therapeutics appoints Gokhale to its Scientific Advisory Board

Feb 26, 2026, 9:10 AM EST - 2 months ago

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

2026-02-23T13:53:01.000Z - 2 months ago

Akari Therapeutics appoints Olga Anczukow to SAB

Feb 18, 2026, 9:05 AM EST - 2 months ago

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Feb 11, 2026, 8:45 AM EST - 3 months ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

Feb 10, 2026, 7:00 PM EST - 3 months ago

Akari Therapeutics, Transcript: Study update

Feb 5, 2026, 9:15 AM EST - 3 months ago

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

2026-01-26T13:51:30.000Z - 3 months ago

Akari Therapeutics files patent covering AKTX-102

Jan 26, 2026, 8:45 AM EST - 3 months ago

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Jan 9, 2026, 9:00 AM EST - 4 months ago

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Jan 8, 2026, 9:15 AM EST - 4 months ago

Akari Therapeutics to Present at the 2026 Biotech Showcase

2026-01-05T11:40:46.000Z - 4 months ago

Akari Therapeutics initiated with a Buy at Ladenburg

2025-12-30T14:20:10.000Z - 4 months ago

Akari Therapeutics CEO says company ‘progressing to critical inflection points’

Dec 30, 2025, 9:15 AM EST - 4 months ago

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

2025-12-23T13:40:49.000Z - 4 months ago

Akari Therapeutics initiates GMP manufacturing of AKTX-101

Dec 23, 2025, 8:30 AM EST - 4 months ago

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Dec 18, 2025, 8:30 AM EST - 5 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

2025-12-16T14:35:52.000Z - 5 months ago

Akari Therapeutics announces $5M financing

Dec 16, 2025, 9:29 AM EST - 5 months ago

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

2025-12-09T13:46:08.000Z - 5 months ago

Akari Therapeutics announces preclinical data on AKTX-101

Dec 9, 2025, 8:40 AM EST - 5 months ago

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

2025-12-04T14:16:32.000Z - 5 months ago

Akari Therapeutics provides update, highlights ADC payload innovation

Dec 4, 2025, 9:00 AM EST - 5 months ago

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment

Nov 25, 2025, 9:00 AM EST - 5 months ago

Akari Therapeutics Announces Release of the Next CEO Corner Segment

2025-11-18T14:44:50.000Z - 6 months ago

Akari Therapeutics appoints Farag as interim CFO

Nov 18, 2025, 8:35 AM EST - 6 months ago

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

2025-11-10T13:51:19.000Z - 6 months ago

Akari Therapeutics announces presentation of mechanism of action data for PH1

Nov 10, 2025, 8:30 AM EST - 6 months ago

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Nov 4, 2025, 9:25 AM EST - 6 months ago

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Oct 30, 2025, 8:35 AM EDT - 6 months ago

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Oct 22, 2025, 9:05 AM EDT - 7 months ago

Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 15, 2025, 8:30 AM EDT - 7 months ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Oct 9, 2025, 8:45 AM EDT - 7 months ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Oct 3, 2025, 9:30 AM EDT - 7 months ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Sep 24, 2025, 8:45 AM EDT - 8 months ago

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Sep 17, 2025, 8:45 AM EDT - 8 months ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Sep 5, 2025, 6:45 AM EDT - 8 months ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 8 months ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 14, 2025, 9:15 AM EDT - 9 months ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 23, 2025, 8:55 AM EDT - 10 months ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 22, 2025, 8:45 AM EDT - 10 months ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jun 25, 2025, 9:00 AM EDT - 11 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 18, 2025, 8:50 AM EDT - 11 months ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

May 29, 2025, 2:20 PM EDT - 1 year ago

Akari Therapeutics, Transcript: Webull Corporate Connect: Virtual Biotech Investment Webinar

May 29, 2025, 9:15 AM EDT - 1 year ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 22, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 19, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

May 15, 2025, 8:05 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 8:45 AM EDT - 1 year ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Apr 22, 2025, 9:05 AM EDT - 1 year ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Mar 20, 2025, 8:35 AM EDT - 1 year ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 3, 2025, 9:00 AM EST - 1 year ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Feb 19, 2025, 9:00 AM EST - 1 year ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 3, 2025, 8:00 AM EST - 1 year ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Dec 18, 2024, 8:51 AM EST - 1 year ago

Akari Therapeutics Announces Key Leadership Appointments

Nick1971 May. 9 at 12:08 AM

0 · Reply

topstockalerts May. 5 at 11:31 PM

After Hours Top Gainers PT2 $COMP $SMCI $FLEX $CYPH $AKTX

0 · Reply

Amricanopyscho May. 5 at 10:42 PM

$AKTX went on low volume

0 · Reply

MTN May. 5 at 3:04 PM

$AKTX still needs over a 3000% run up to make holders of the last few years whole. Just break even.

0 · Reply

MTN May. 5 at 3:03 PM

$AKTX just trying to sucker in buyers. Until they announce a major partnership, this is just MMs and traders trying to take your hard earned money. Don't believe me? Look at the chart.

0 · Reply

KayJ_ May. 4 at 8:57 PM

$AUUD $PAVS $MODD $AKTX into

0 · Reply

coachmc Apr. 29 at 6:27 PM

$AKTX the volume here is laughable , also the MC and spread

0 · Reply

BillionerOfKing Apr. 28 at 1:34 PM

$AKTX Current Stock Price: $5.60

0 · Reply

MTN Apr. 27 at 3:37 PM

$AKTX -$2,114.55 (99.74%) down from the ATH. Don't waste your time here.

0 · Reply

Stock_Catcher Apr. 27 at 12:35 PM

$AKTX Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

0 · Reply

DARKP00L Apr. 21 at 1:14 PM

$AKTX 09:01 on Apr. 21 2026 Akari Therapeutics Announces Abstract Acceptance For Online Publication At American Society Of Clinical Oncology Annual Meeting 2026 #tradeideas

0 · Reply

MTN Apr. 20 at 5:18 PM

$AKTX holders from a few years ago would need over 3000% run up just to break even. Save your time, money and headaches, let these losers go bankrupt on their own dime, not yours.

0 · Reply

MTN Apr. 20 at 5:17 PM

$AKTX More bs pre-clinical data - that no large pharma will pay for....again, story of AKTX. Promising pipeline, huge patent library, nothing to show for it but burning hundreds of millions - don't believe me? Look at their 8k or zoom out on the share price. Insane to think this was once viewed the same way $VKTX was.

1 · Reply

BecauseOfScout Apr. 20 at 5:13 PM

$AKTX Interesting

0 · Reply

focafoca99 Apr. 20 at 1:34 PM

$AKTX reported positive preclinical data for AKTX-101, highlighting differentiated cytotoxicity for its TROP2 ADC payload targeting RNA splicing. https://www.rapidticker.com/news/aktx-akari-therapeutics-reports-positive-preclinical-e36ccb

0 · Reply

durocali Apr. 20 at 12:52 PM

$AKTX expected bigger positive impact on the stock with today's reporting. typical sell the news action or something underneath here?

0 · Reply

Sashko2018 Apr. 20 at 12:51 PM

$AKTX 150$

1 · Reply

Sashko2018 Apr. 20 at 12:51 PM

$AKTX

0 · Reply

OpenOutcrier Apr. 20 at 12:44 PM

$AKTX (-4.8% pre) Bladder, lung and breast models show Akari drug beats TROP2 rivals https://ooc.bz/l/99270

0 · Reply

scolii Apr. 20 at 12:40 PM

$AKTX this stopped me from buying in on this news. thanks. shitter hit red in 3 minutes

0 · Reply

DARKP00L Apr. 20 at 12:39 PM

$AKTX 08:36 on Apr. 20 2026 Akari Therapeutics' AKTX-101 Shows Superior Preclinical Potency Versus Leading TROP2 ADCs Across Bladder, Lung, And Breast Cancer Models #tradeideas

0 · Reply

Market Cap	7.15M
Revenue (ttm)	0.00
Net Income (ttm)	-17.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.02

Volume	4,200
Avg Vol	36,229
Day's Range	N/A - N/A
Shares Out	1.15M
Stochastic %K	78%
Beta	0.64
Analysts	Sell
Price Target	$27.00